__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
Beovu is indicated in adults for the treatment of neovascular (wet) AMD.1
AMD, age-related macular degeneration; NICE, National Institute for Health and Care Excellence; SMC, Scottish Medicines Consortium.
References
- Beovu Summary of Product Characteristics, 2020.
- National institute for Health and Care Excellence (2021) Brolucizumab for treating wet age-related macular degeneration (NICE guideline 672). Available at https://www.nice.org.uk/guidance/ta672. [Accessed 25 March 2021].
- https://www.scottishmedicines.org.uk/medicines-advice/brolucizumab-beovu-full-smc2272/ [Accessed 25 March 2021].
About the molecule and how it works.Show more
Visual acuity outcomes with Beovu in clinical trials.Show more
Anatomical outcomes with Beovu in clinical trials.Show more
Treatment interval outcomes with Beovu in clinical trials.Show more
Downloadable summaries of the HAWK and HARRIER Phase III clinical trials.Show more